

DECIPHER PROSTATE BIOPSY

WHAT IS THE DECIPHER TEST?

Decipher is a tumor-based test that provides genomic information to help you and your physician make decisions about your care



DECIPHER BIOPSY

- Performed on your prostate biopsies diagnosed as positive for cancer
- Helps determine which men may be suitable candidates for active surveillance, which may need local therapy, and which may need intensified therapy



ACCESS FOR ALL PATIENTS

- Covered by Medicare
- Covered by select private insurers
- Generous financial assistance program for patients - Decipher Assist

Contact the Decipher Customer Support Team at 1.888.792.1601 or cs@decipherbio.com



Decipher Biosciences
Information for Life

To learn more about Decipher, contact the Decipher Customer Support Team at 1.888.792.1601 or cs@decipherbio.com

Copyright © 2020 Decipher Biosciences, Inc.
Testing is performed by Decipher Corp., a Decipher Biosciences company

DECIPHER PROSTATE BIOPSY

AFTER BIOPSY



DECIPHER PROSTATE BIOPSY

Decipher Biopsy helps you and your doctor decide next steps in your prostate cancer care

DECIPHER PROSTATE BIOPSY

NOT ALL PROSTATE CANCERS ARE ALIKE

THE DECIPHER TEST HELPS DETERMINE:

- Is active surveillance through PSA monitoring sufficient for me?
- Is localized treatment sufficient for me?
- Do I need more than one therapy (multi-modal therapy)?

Decipher Test Result	Patient Management Recommendations
Decipher Biopsy Low Risk	Favorable prognosis – may be suitable for active surveillance and may have excellent outcomes with local therapy alone, such as surgery or radiotherapy ¹⁻⁴
Decipher Biopsy High Risk	Unfavorable prognosis – may not be suitable for active surveillance and may benefit from intensification with multi-modal therapy ¹⁻⁴

ANSWER THE FOLLOWING QUESTIONS TO DETERMINE IF DECIPHER® IS RIGHT FOR YOU:

Did your doctor indicate that the following applied to you after a biopsy positive for prostate cancer?

Medicare Indications

- Gleason Score 3+3=6, 3+4=7, or 4+3=7
- PSA 20 ng/mL or less
- Stage T1a, T1b, T1c, T2a, T2b, or T2c

If you answered **yes** to all of the questions above, then the Decipher Biopsy test may play a role in determining what type of therapy you may need



This test is covered by Medicare and select private insurers. We have a generous financial aid program, Decipher Assist, for qualified patients.

References

1. Klein, E. A. et al. Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. *Urology* (2016). doi:10.1016/j.urol.2016.01.012
2. Berlin, A. et al. Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image-guided radiotherapy without hormone therapy. *Int. J. Radiat. Oncol.* (2018). doi:10.1016/j.ijrobp.2018.08.030
3. Nguyen, P. L. et al. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. *Eur. Urol.* (2017). doi:10.1016/j.eururo.2017.05.009
4. Kim, H. L. et al. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. *Prostate Cancer Prostatic Dis.* (2018). doi:10.1038/s41391-018-0101-6



Contact your doctor to find out how Decipher might play a role in your treatment planning or contact the Decipher Customer Support Team at 1.888.792.1601 or cs@decipherbio.com